GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Covidien PLC (FRA:6COP) » Definitions » ROC (Joel Greenblatt) %

Covidien (FRA:6COP) ROC (Joel Greenblatt) % : 69.08% (As of Dec. 2014)


View and export this data going back to . Start your Free Trial

What is Covidien ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Covidien's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2014 was 69.08%.

The historical rank and industry rank for Covidien's ROC (Joel Greenblatt) % or its related term are showing as below:

FRA:6COP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 9.46   Med: 49.17   Max: 94.45
Current: 54.83

During the past 13 years, Covidien's highest ROC (Joel Greenblatt) % was 94.45%. The lowest was 9.46%. And the median was 49.17%.

FRA:6COP's ROC (Joel Greenblatt) % is not ranked
in the Medical Devices & Instruments industry.
Industry Median: -0.83 vs FRA:6COP: 54.83

Covidien's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 4.70% per year.


Covidien ROC (Joel Greenblatt) % Historical Data

The historical data trend for Covidien's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Covidien ROC (Joel Greenblatt) % Chart

Covidien Annual Data
Trend Sep05 Sep06 Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.23 57.36 46.36 54.95 61.48

Covidien Quarterly Data
Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.87 75.01 39.11 47.99 69.08

Competitive Comparison of Covidien's ROC (Joel Greenblatt) %

For the Medical Instruments & Supplies subindustry, Covidien's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Covidien's ROC (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Covidien's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Covidien's ROC (Joel Greenblatt) % falls into.



Covidien ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2014 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1188.832 + 1092.608 + 722.456) - (1257.12 + 0 + 511.384)
=1235.392

Working Capital(Q: Dec. 2014 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1176.761 + 1153.242 + 726.656) - (1544.955 + 0 + 0)
=1511.704

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Covidien for the quarter that ended in Dec. 2014 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2014 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2014  Q: Dec. 2014
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=2046.964/( ( (1570.624 + max(1235.392, 0)) + (1609.024 + max(1511.704, 0)) )/ 2 )
=2046.964/( ( 2806.016 + 3120.728 )/ 2 )
=2046.964/2963.372
=69.08 %

Note: The EBIT data used here is four times the quarterly (Dec. 2014) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Covidien  (FRA:6COP) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Covidien ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Covidien's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Covidien (FRA:6COP) Business Description

Traded in Other Exchanges
N/A
Address
Covidien PLC formerly known as Covidien Ltd. was incorporated in Bermuda in 2000 as a wholly-owned subsidiary of Tyco International Ltd. In June 2009, Covidien plc announced that one of its subsidiaries has completed the acquisition of VNUS Medical Technologies, Inc. In September 2009, the Company completed the acquisition of Power Medical Interventions Inc. In November 2009, the Company completed the acquisition of Aspect Medical Systems Inc. The Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. Its products are found in almost every hospital in the United States. Its mission is to create and deliver innovative healthcare solutions, developed in ethical collaboration with medical professionals. It operates through two segments: Medical Devices and Medical Supplies. The Medical Devices segment includes the development, manufacture and sale of endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products, and other medical products. The Medical Supplies segment includes the development, manufacture and sale of nursing care products, medical surgical products, SharpSafety products and original equipment manufacturer products. Competitors of Medical Devices segment include diversified healthcare companies, such as Johnson & Johnson, Boston Scientific, Baxter and C.R. Bard. Its Nursing Care products include: Curity and Kerlix and Medical Surgical products include: Medi-Trace. The Company holds more than 13,000 patents and have over 10,500 patent applications pending in the United States and in certain other countries that relate to aspects of the technology used in many of its products. The Company is subject to numerous federal, state and local environmental protection and health and safety laws and regulations both within and outside the United States.

Covidien (FRA:6COP) Headlines

No Headlines